Hansa Biopharma (HNSA) Q2 2024 earnings summary

Executive summary

• Achieved third consecutive quarter of strong sales, with Q2 2024 revenue of SEK 54.2 million (47.1 MSEK from Idefirix), and expanded commercial access in all top five European markets, including first sales in Italy.

• Advanced pipeline with full randomization of the pivotal U.S. ConfIdeS Phase 3 trial in kidney transplantation, and significant progress in anti-GBM and PAES studies.

• Financing round in Q2 2024 raised SEK 372 million, extending cash runway into 2026 and supporting US launch preparations.

• Restructuring program reduced SG&A and R&D expenses, with decreased staffing and external service costs.

Financial highlights

• Q2 2024 revenue was SEK 54.2 million, with SEK 47.1 million in product sales before a SEK 19.9 million provision for price and volume discounts.

• Q2 2024 operating loss was SEK 187 million; H1 2024 operating loss was SEK 347 million, reflecting lower SG&A and R&D expenses but higher cost of goods sold.

• Cash and cash equivalents at June 30, 2024, totaled SEK 705 million, up from SEK 541 million at March 31, 2024, due to the share issue.

• SG&A expense in Q2 was SEK 88 million, with restructuring activities reducing costs; R&D expense was SEK 92 million.

Outlook and guidance

• Expect continued growth in Idefirix sales as new centers and markets come online, especially in Italy, Spain, Germany, France, and the UK.

• Gross margin is expected to improve in the second half of 2024 as manufacturing costs normalize and sales increase.

• Cash runway extended into 2026, with further reductions in burn rate anticipated from both cost savings and top-line growth.

• Data readouts expected in 2025 for the U.S. ConfIdeS trial, European post-authorization efficacy study, and key autoimmune and gene therapy trials.

• Planned BLA submission for imlifidase in the US in 2H 2025.